

WO03043607

Publication Title:

A PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE OF A BETA-LACTAM ANTIBIOTIC

Abstract:

Abstract of WO03043607

An improved stable pharmaceutical composition for controlled release of an active ingredient comprises a betalactam antibiotic such as cephalexin, cefaclor or their pharmaceutically acceptable hydrates, salts or esters as active ingredient, a calcium salt and a mixture of hydrophilic po 1057 lymers selected from the group consisting of at least one sodium alginate and one xanthan gum and with or without hydroxypropyl methylcellulose, said composition optionally containing probenecid. The composition may also contain one or more of a water soluble and/or water dispersible diluent, wherein the quantities of the hydrophilic polymers and water soluble and/or water dispersible diluents are such that the therapeutically effective active ingredient is released at a rate suitable for once or twice daily administration of the pharmaceutical composition. Data supplied from the esp@cenet database - Worldwide

Courtesy of <http://v3.espacenet.com>

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 May 2003 (30.05.2003)

PCT

(10) International Publication Number
WO 03/043607 A1

(51) International Patent Classification⁷: **A61K 9/22**, 31/545, 31/24 (74) Agents: MAJUMDAR, S. et al.; S. Majumdar & Co., 5, Harish Mukherjee Road, Calcutta 700 025 (IN).

(21) International Application Number: **PCT/IN01/00204**

(22) International Filing Date:
19 November 2001 (19.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (*for all designated States except US*): **LUPIN LIMITED** [IN/IN]; 159 C.S.T. Road, Kalina, Santacruz (East), Mumbai 400 098, Maharashtra (IN).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **SEN, Himadri** [IN/IN]; Lupin Laboratories Limited, A-28/1 MIDC Chikalthana, Aurangabad 431 210, Maharashtra (IN). **KSHIRAGAR, Rajesh, Suresh** [IN/IN]; Lupin Laboratories Limited, A-28/1 MIDC Chikalthana, Aurangabad 431 210, Maharashtra (IN). **BHAMARE, Shailesh, Suresh** [IN/IN]; Lupin Laboratories Limited, A-28/1 MIDC Chikalthana, Aurangabad 431 210, Maharashtra (IN).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KH, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/043607 A1

(54) Title: A PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE OF A BETA-LACTAM ANTIBIOTIC

(57) Abstract: An improved stable pharmaceutical composition for controlled release of an active ingredient comprises a betalactam antibiotic such as cephalexin, cefaclor or their pharmaceutically acceptable hydrates, salts or esters as active ingredient, a calcium salt and a mixture of hydrophilic polymers selected from the group consisting of at least one sodium alginate and one xanthan gum and with or without hydroxypropyl methylcellulose, said composition optionally containing probenecid. The composition may also contain one or more of a water soluble and/or water dispersible diluent, wherein the quantities of the hydrophilic polymers and water soluble and/or water dispersible diluents are such that the therapeutically effective active ingredient is released at a rate suitable for once or twice daily administration of the pharmaceutical composition.

AN PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE OF A BETA-LACTAM ANTIBIOTIC

FIELD OF THE INVENTION

This invention relates to an improved stabilized pharmaceutical composition of modified release tablets comprising a betalactam antibiotic or their pharmaceutically acceptable hydrates, salts or esters as the active ingredient, which would provide for controlled release of said actives and will also be capable of maintaining its dissolution characteristics upon storage, at ambient and accelerated conditions. The stabilized composition of the invention is also adapted to withstand the peristaltic pressure in the stomach and intestine, maintain the integrity of the composition and thereby avoid problems of dose dumping. Advantageously, the composition of the invention can be selectively provided to favour desired release of the therapeutically effective active ingredient such as at a rate suitable for once or twice daily administration of the pharmaceutical composition. The composition optionally contains probenecid as an antibiotic adjuvant.

15

BACKGROUND OF THE INVENTION

United States Patent No. US 6,267,986 B1 teaches preparation of a controlled release pseudoephedrine composition in combination with an antihistamine comprising two discrete zones. The first discrete zone comprises pseudoephedrine, one or more hydrophilic polymers, 20 a salt of a polyuronic acid and a pharmaceutically acceptable salt of a group II metal ion and the second discrete zone comprises an antihistamine.

United States Patent No. US 5,419,917 discloses a controlled release hydrogel formulation for substantially zero-order release rate of drug from the hydrogel which is based on the use 25 of an effective amount of a pharmaceutically acceptable ionizable compound. The hydrogel forming agent are being selected from the group consisting of hydroxypropyl methylcellulose, sodium alginate and xanthan and the ionizable compound being selected from the group consisting of alkali metal chlorides, organic acids, alkali metal sulfates and alkali metal alkyl sulfates, dihydrogen sodium phosphate and monohydrogen sodium 30 phosphate.

A sustained release cephalexin tablet containing xanthan gum and sodium alginate as matrix formers was evaluated in human volunteers using *in-vitro/in-vivo* correlations. The optimized

formulation containing 5 % xanthan gum and 8 % sodium alginate, decided on the basis of response surface analysis and computer simulation of cephalexin plasma levels versus time curves was used for clinical trials and was found to prolong the cephalexin blood levels up to 8 hours in humans. However, the relative bioavailability of cephalexin was reduced by about 5 30 % and very little absorption was seen after six to eight hours, rendering the formulation not very useful for once daily regimen (see Dhopeshwarkar V., O'Keeffe J. C., Zatz J. L., Deeter R. and Horton M., *Drug Develop. Ind. Phar.*, 20, 1851, 1994).

Our PCT Application No. PCT/IN00/00112 relates to a pharmaceutical composition of 10 modified release tablets comprising a betalactam antibiotic or their pharmaceutically acceptable hydrates, salts or esters as the active ingredient, and a mixture of hydrophilic polymers selected from the group consisting of at least one sodium alginate and at least one xanthan gum as controlled release matrix, and optionally probenecid. Inclusion of probenecid allows reduction in the amount of active incorporated in the polymeric matrix but can still 15 provide desired once daily profile. The resulting modified release matrix formulation not containing probenecid may be administered in a once or twice daily regimen and the resulting modified release matrix formulation containing probenecid may be administered in a once daily regimen. However, it was observed that tablets become soft and irregular after about 6 hours of *in-vitro* dissolution studies, the integrity of the tablet and its shape is not maintained 20 at a later stage after hydration. This soft irregular mass of the composition may not withstand the peristaltic pressure in the stomach and intestine, which could possibly lead to dose dumping in later stage.

Further, it was observed that the release of the active ingredient was faster from the samples 25 stored for stability study under ambient and accelerated conditions, when compared to initial stage *in-vitro* dissolution data, which may render the composition ideally not suited for use as a controlled release composition having desired release profile.

OBJECTS OF THE INVENTION

30 The basic object of the present invention is to provide an improved stable composition of a betalactam antibiotic such as cephalexin, cefaclor or their pharmaceutically acceptable hydrates, salts or esters in a modified release matrix formulation, which would avoid the

above discussed problems associated with stability of the composition and integrity of the composition and consequential dose dumping.

A further object of the present invention is to provide an improved stable composition of a
5 betalactam antibiotic such as cephalexin, cefaclor or their pharmaceutically acceptable hydrates, salts or esters in a modified release matrix formulation, optionally containing probenecid such that the composition maintains its dissolution characteristics upon storage, at ambient and accelerated conditions.

10 Another object of the present invention is to provide an improved stable composition of a betalactam antibiotic such as cephalexin, cefaclor or their pharmaceutically acceptable hydrates, salts or esters in a modified release matrix formulation, optionally containing probenecid such that the integrity and shape of the composition is maintained even at the later stage of hydration.

15

SUMMARY OF THE INVENTION

Thus according to one aspect of the present invention there is provided a stable improved pharmaceutical composition for controlled release of an active ingredient comprising a controlled release matrix comprising i)a betalactam antibiotic or their pharmaceutically
20 acceptable hydrates, salts or esters as the active ingredient in amounts of 30 % to 90 % by weight, ii)a mix of hydrophilic polymers in amount of 1 % to 25 % selected from the group consisting of at least one sodium alginate in amounts of 0.1 % to 20 %, and at least one xanthan gum in amounts of 0.1 % to 20 % and iii) a calcium salt in an amount of 8 % to 20 % by weight of sodium alginate.

25

In accordance with a preferred aspect the composition of the invention, in particular the hydrophilic polymers used therein incorporate along with the said sodium alginate and said xanthan gum optionally at least one hydroxypropyl methylcellulose, preferably in amount of 0.1 % to 20 % by weight of the controlled release matrix.

30

It is found that the above selective controlled release formulation of the invention avoids the shortcoming of integrity of the matrix composition comprising at least one sodium alginate and at least one xanthan gum and also takes care of the desired controlled release profile of

the active. By inclusion of a hydroxypropyl methylcellulose in to the matrix, the integrity of the tablet is improved and its shape is maintained at a later stage after hydration so that it withstands the peristaltic pressure in the stomach and intestine thereby obviating the possibility of dose dumping.

5

Advantageously, the selective use of a calcium salt such as calcium sulphate in the defined range as disclosed above is also found to be advantageous in use with sodium alginate as a polymer matrix material for controlled release formulation. This is because calcium alginate when used as such in sustained release preparation forms a water insoluble gel, which has 10 reduced diffusivity and erosion of gel layer. But addition of the selective calcium salt in dry state in the polymer matrix containing sodium alginate acts as a matrix stabilizing agent by *in situ* formation of a localized calcium alginate gel, as after ingestion of the composition, the solvent front passes up to the core of the composition resulting in formation of gel layer in a manner such that a gel layer contains combination of sodium and calcium alginate, which 15 would erode faster in comparison to a gel layer containing only calcium alginate leading to desired release profile of the active from the composition.

Importantly, the above composition of the invention attends to the problems of stability of the tablets after storage at ambient and accelerated conditions, by selective incorporation of a 20 calcium salt such as calcium sulphate in a defined range as matrix stabilising agent.

In accordance with a preferred aspect, the invention proposes the use of a hydroxypropyl methylcellulose into the matrix, which forms a strong gel structure. These hydrophilic polymers when used in appropriate concentrations, form the integrated matrix which provides 25 the desired release profile, when the delivery system travels through the GIT, having varying physiological condition. Surprisingly, the polymers in appropriate combinations are not only effective compared to other commonly used polymers, but works at low concentrations. The combination of these polymers compliment each other such that, it overcomes the deficiencies associated with their use, when used alone.

30

The composition of the invention can optionally also contain one or more water soluble and/or water dispersible diluents, wherein the quantities of the hydrophilic polymers and water soluble and/or water dispersible diluents are such that the therapeutically effective

active ingredient is released at a rate suitable for once or twice daily administration of the pharmaceutical composition. Inclusion of probenecid allows reduction in the amount of active incorporated in the hydrophilic polymer matrix but still provides the desired once a day profile.

5

The preferred betalactam antibiotic is selected from cephalexin, cefaclor or their pharmaceutically acceptable hydrates, salts or esters.

10 The modified release matrix formulation not containing probenecid prepared according to present invention may be administered once or twice daily. For Example, the effective therapeutic dose of the active that can be administered by compositions of present invention include 375 mg to 500 mg active twice daily or 750 mg to 1500 mg active once daily.

15 The modified release matrix formulation containing probenecid prepared according to present invention may be administered once daily. For example, the effective therapeutic dose of the active that can be administered by compositions of present invention include 500 mg to 1000 mg active and 500 mg to 1000 mg probenecid once daily.

20 It is to be understood that both the foregoing general description and the following detailed description are exemplary, but are not restrictive, of the invention.

DETAILED DESCRIPTION OF THE INVENTION

25 The composition of this invention is in the form of a matrix tablet comprising the active ingredient, hydrophilic polymers, a calcium salt, water soluble and/or water dispersible diluents, pharmaceutically acceptable tablet excipients, and antibiotic adjuvant if any, for controlling the release of active ingredients.

30 According to the present invention, the active ingredient is a betalactam antibiotic such as cephalexin, cefaclor or their pharmaceutically acceptable hydrates, salts or esters in a controlled release matrix. The cephalexin, cefaclor or their pharmaceutically acceptable hydrates, salts or esters may be present in an amount from about 30 % to about 90 % by weight of the controlled release matrix.

Further, the cephalexin, cefaclor or their pharmaceutically acceptable hydrates, salts or esters may be present in an amount from 100 mg to 2000 mg.

- 5 Examples of other cephalosporin antibiotics which may be used include cefuroxime, cefamandole, cefoxitin, cephalothin, moxalactam, cephapirin, ceffizoxime, cefonicid and, pharmaceutically acceptable hydrates, salts or esters thereof. Examples of other betalactam antibiotics, which may be used, are amoxicillin, ampicillin, and cloxacillin.
- 10 Examples of the calcium salts useful in the present invention are calcium sulphate, calcium citrate, disodium calcium edetate, calcium lactate, calcium ascorbate, calcium gluconate, calcium chloride. The preferred calcium salt is calcium sulphate.

Xanthan gum when used as a matrix forming agent in sustained release tablets, releases the drug slightly faster in acidic media, due to more rapid initial surface erosion than at higher pH. After hydration of the gum the drug release is essentially pH independent but the release of drug decrease exponentially.

- 20 Alginic acid is insoluble in aqueous media. However, as the pH is raised above 3, the alginic acid is partly converted to a soluble salt. Complete neutralization occurs around pH 4, where the alginic acid is completely converted to its corresponding salt. Sodium, potassium, magnesium and ammonium salts are examples of water-soluble alginate salts. Neutralization by calcium, barium and other multivalent alkali materials will produce insoluble alginate salts.

25

Thus when sodium alginate is used along with xanthan gum to form a controlled release matrix, it reduces the initial bursting effect and in later stages acts as a channeling agent to increase the release rate of the active.

- 30 It is known in the art that in gastric fluid the hydrated sodium alginate is converted into a porous, insoluble alginic acid skin. Once passed into the higher pH of the intestinal tract, the alginic acid skin is converted to a soluble viscous layer.

- Alginate powders like sodium alginate when stored under cool, dry conditions in sealed container is stable and does not undergo microbial spoilage but due to slow reduction in degree of polymerization, its properties may be affected by storage. This is most easily observed as a reduction in viscosity of soluble alginates. This may be the reason for observed
- 5 faster release of the active from the composition comprising of matrix prepared with a sodium alginate, a xanthan gum and a hydroxypropyl methylcellulose, on stability as compared to freshly prepared compositions.
- Many drugs and drug metabolites are actively secreted by the proximal tubular active
- 10 transport mechanism and interactions may arise from competition for these systems. Particularly with antibiotic therapy, active tubular secretion is a significant route of elimination. Drugs that use the same active transport system in the kidney tubules can compete with one another for secretion. Probenecid belongs to this class of drugs, which is able to compete successfully with some other drugs for an active secretion mechanism in the
- 15 kidney tubule. This prevents them from being secreted into the tubular filtrate. Probenecid is later passively reabsorbed from the kidney tubules. Probenecid was extremely useful in the early days of penicillin when the combination raised and prolonged penicillin plasma levels. Inhibition of the urinary excretion of penicillin and some cephalosporins has been used as a device to increase the biliary excretion of these agents, thereby raising the antibiotic
- 20 concentrations in the biliary tract. This has been used to improve the efficacy of antibiotic treatment (Antibiotic and Chemotherapy: Anti-infective agents and their use in therapy, 7th edition, Ed. by O'grady F., Finch R.G., Lambert H.P., Greenwood D.; Churchill Livingstone, 1997).
- 25 In the present invention probenecid is used as an antibiotic adjuvant for reducing the elimination rate and increasing the half-life of the therapeutically active ingredient. Inclusion of probenecid allows reduction in the amount of active incorporated in the hydrophilic polymer matrix but still provides the desired once a day profile.
- 30 For the purpose of the composition of the invention, sodium alginate used is preferably characterized by their viscosities in a 1 % w/w aqueous solution as low viscosity (about 75 to about 150 cPs), medium viscosity (about 200 to about 400 cPs) and high viscosity (about 600

to about 1000 cPs); xanthan gum may be characterized as low viscosity (about 600 to about 1500 cPs), medium viscosity (about 1550 to about 1850 cPs) and high viscosity (greater than about 1900 cPs); and hydroxypropyl methylcellulose may be characterized by their viscosity in a 2 % w/w aqueous solution as low viscosity (less than 1000 cps), medium viscosity (about 5 1000 cps to about 10,000 cps) and high viscosity (greater than about 10,000 cps).

The different viscosity grade polymers may be used in the present invention, but in order to utilize minimum possible concentrations of the polymer to achieve the desired profiles, without compromising on the integrity of the matrix, medium or high viscosity grade 10 polymers are preferred.

In a preferred embodiment of the present invention, the pharmaceutical composition comprises from about 30 % to about 90 % by weight of cephalexin, cefaclor or their pharmaceutically acceptable hydrates, salts or esters and about 1 % to about 25 % by weight 15 of hydrophilic polymers comprising of sodium alginate in an amount from about 0.1 % to about 20 % by weight, xanthan gum in an amount from about 0.1 % to about 20 % by weight, and hydroxypropyl methylcellulose in an amount from about 0.1 % to about 20 % by weight of controlled release matrix; and calcium sulphate in an amount from about 8 % to about 20 % by weight of sodium alginate.

20 In a more preferred embodiment of the present invention, the pharmaceutical composition comprises from about 30 % to about 90 % by weight of cephalexin, cefaclor or their pharmaceutically acceptable hydrates, salts or esters and about 1 % to about 20 % by weight of hydrophilic polymers comprising of a medium or high viscosity grade sodium alginate in 25 an amount from about 0.1 % to about 15 % by weight, a medium or high viscosity grade xanthan gum in an amount from about 0.1 % to about 15 % by weight, and a medium or high viscosity grade hydroxypropyl methylcellulose in an amount from about 0.1 % to about 15 % by weight of controlled release matrix; and calcium sulphate in an amount from about 8 % to about 16 % by weight of sodium alginate.

30 In one more preferred embodiment of the present invention, the pharmaceutical composition comprises from about 30 % to about 90 % by weight of cephalexin, cefaclor or their

pharmaceutically acceptable hydrates, salts or esters and about 1 % to about 18 % by weight of hydrophilic polymers comprising of a medium or high viscosity grade sodium alginate in an amount from about 1 % to about 10 % by weight, a medium or high viscosity grade xanthan gum in an amount from about 1 % to about 10 % by weight, and a medium or high viscosity grade hydroxypropyl methylcellulose in an amount from about 1 % to about 10 % by weight of controlled release matrix; and calcium sulphate in an amount from about 10 % to about 14 % by weight of sodium alginate.

Probenecid may be formulated as a controlled release or immediate release part, in an amount from about 250 mg to about 1000 mg.

10

The inclusion of probenecid in compositions of the present invention allows lowering of amount of active ingredient used. For example, therapeutically effective dose of the active ingredient that can be administered by the composition of the present invention containing probenecid include 500 to 1000 mg active with 500 to 1000 mg probencid once daily, and therapeutically effective dose of the active that can be administered by the composition of the present invention not containing probenecid include 750 mg to 1500 mg of active once daily.

The composition may contain one or more of pharmaceutically acceptable excipients in an amount of about 1 % to about 30 % by weight of the total weight of the composition. These excipients may be water soluble or water dispersible. Examples of water soluble diluents that may be used in the present invention include lactose, mannitol, glucose, sorbitol, maltose, dextrates, dextrins and the like. Water dispersible diluent refers to insoluble pharmaceutical excipients, which disperse readily in water such as microcrystalline cellulose, starch, pre-gelatinized starch, magnesium aluminum silicates and the like. In one preferred embodiment, the water soluble diluent is lactose in amounts from about 4 % to about 20 % by weight of the composition. In another preferred embodiment, the water dispersible diluent is microcrystalline cellulose present in amount from about 4 % to about 20 % by weight of the composition.

30 The composition may also contain tablet lubricants, at a concentration in the range of about 0.2 % to 5 % by weight of the composition. The lubricants that may be used include talc,

stearic acid, magnesium stearate, colloidal silicon dioxide, calcium stearate, zinc stearate, hydrogenated vegetable oil and the like. Preferably the lubricant is magnesium stearate.

- 5 The immediate release probenecid part of the present invention contains a disintegrating agent at concentration in the range of about 2 % to about 9 % by weight of immediate release part. Preferably the disintegrating agent is sodium starch glycolate.

The pharmaceutical composition of the present invention may be prepared by procedures well known to formulation chemists. The method of manufacturing can affect the release characteristics of the composition. All the hydrophilic polymers are uniformly pre-blended with calcium sulphate, followed by the active ingredient; one or more water soluble or water dispersible diluents are either mixed together with lubricants and the blend is directly compressed into tablets or are granulated by compaction followed by sieving and the granules obtained are compressed into tablets. The active ingredient can be given as controlled release tablets for once or twice a day administration or as controlled release tablet along with separate probenecid tablets as a combipack to be administered simultaneously or coupled with probenecid into a single monolithic or bilayered tablets for once a day administration. The fines incorporated in the blend of active granules form about 12 % to about 30 % by weight of controlled release part, preferably from about 12 % to about 20 %.

20

For the purpose of this patent application, fines denote the particles having size less than 250 microns.

25 The above-mentioned process has the advantage over its granulation by aqueous or non-aqueous vehicle used conventionally. The active ingredient such as cephalexin or cefaclor, which are sensitive to moisture and heat, can be effectively processed without any difficulty. The polymers used in the composition of present invention, xanthan gum and sodium alginate also are unstable above 60° C and 70° C respectively. As the process is devoid of use of any solvents the potential problem of limiting the residual organic solvent is eliminated.

30

The controlled release matrix formulation of the present invention is not a mere admixture but has properties different from the sum total of the properties of its ingredients.

The probenecid part of the composition is prepared by mixing probenecid and one or more water soluble or water dispersible diluents together with lubricants and the blend is granulated by compaction followed by sieving and the granules obtained are lubricated and
5 compressed into a tablet. The fines incorporated in the blend form about 10 % to about 30 % by weight of immediate release part, preferably from about 10 % to about 20 %.

The modified release matrix formulation not containing probenecid prepared according to present invention may be administered once or twice daily. For example, the effective
10 therapeutic dose of the active that can be administered by compositions of present invention include 375 mg to 750 mg active twice daily or 750 mg to 1500 mg active once daily.

The modified release matrix formulation containing probenecid prepared according to present invention may be administered once daily. The effective therapeutic dose of the active that
15 can be administered by compositions of present invention include 500 mg to 1000 mg active and 500 mg to 1000 mg probenecid once daily.

The present invention is illustrated hereunder in greater detail in relation to non-limiting exemplary embodiments as per the following examples:

20

EXAMPLES

In the examples given below medium viscosity grade xanthan gum manufactured by Jungbunzlauer, Austria; sodium alginate (Keltone HVCR) manufactured by ISP Alginates; and hydroxypropyl methylcellulose of medium viscosity grade (Methocel K4MTM), high
25 viscosity grade (Methocel K15MTM) manufactured by Dow Chemicals, USA has been employed. The dissolution results are given in respective tables for each example.

30 Effect of calcium sulphate (as a matrix stabilizing agent) on *in-vitro* dissolution of tablets on storage at accelerated condition -

A) Tablet containing hydroxypropyl methylcellulose

Ingredients	Tablet with Calcium Sulphate		Tablet without Calcium Sulphate	
	Weight (mg/tablet)	% w/w	Weight (mg/tablet)	% w/w
Cephalexin	797.82	73.87	797.87	73.87
Sodium Alginate	43.20	4.00	86.40	8.00
Xanthan Gum	54.00	5.00	43.20	4.00
Hydroxypropyl Methylcellulose (Methocel K15M)	54.00	5.00	32.40	3.00
Calcium Sulphate	5.10	0.47	-	-
Lactose Monohydrate	109.63	10.15	103.93	9.62
Magnesium Stearate	16.20	1.50	16.20	1.50
Total	1080	100	1080	100

Time (in hour)	% Cephalexin released (Tablet with calcium sulphate)			% Cephalexin released (Tablet without calcium sulphate)		
	Initial	1M ^a	3M ^b	Initial	1M ^a	3M ^b
1	22.5	22.6	21.6	22.0	22.4	22.9
2	35.7	34.3	33.5	37.1	36.8	37.3
3	45.0	42.3	41.3	44.5	44.7	45.0
4	44.4	43.7	43.5	45.6	50.4	52.1
6	48.5	48.5	49.1	48.6	68.0	73.6
8	58.1	58.2	58.9	56.8	89.0	94.1
10	69.4	69.9	69.8	67.2	99.9	
12	79.1	82.5	78.0	83.3		
14	86.8	91.1	85.2	98.9		

5

^aSamples stored at accelerated conditions of 40° C, 75 % relative humidity for 1 month.^bSamples stored at accelerated conditions of 40° C, 75 % relative humidity for 3 months.

10

Ingredients	Tablet with Calcium Sulphate		Tablet without Calcium Sulphate	
	Weight (mg/tablet)	% w/w	Weight (mg/tablet)	% w/w
Cephalexin	797.87	73.87	800.86	74.14
Sodium Alginate	64.80	7.00	86.40	8.00
Xanthan Gum	75.60	6.00	75.60	7.00
Calcium Sulphate	9.07	0.84	-	-
Lactose Monohydrate	116.46	10.78	100.94	9.35
Magnesium Stearate	16.20	1.50	16.20	1.50
Total	1080	100	1080	100

B) Tablet not containing hydroxypropyl methylcellulose

Time (in hour)	% Cephalexin released (Tablet with calcium sulphate)			% Cephalexin released (Tablet without calcium sulphate)		
	Initial	1M ^a	3M ^b	Initial	1M ^a	3M ^b
1	24.7	23.4	22.2	20.7	21.6	13.0
2	39.0	36.8	34.9	33.0	37.4	37.1
3	48.0	45.1	45.9	43.1	46.3	51.4
4	48.3	48.7	48.1	43.3	53.7	55.0
6	55.0	55.3	57.8	51.1	69.4	76.5
8	66.7	65.7	70.5	65.0	92.2	95.3
10	82.9	75.4	84.5	81.8		
12	87.4	84.7	88.0	96.4		
14	100.0	98.1	92.8	100.4		

^aSamples stored at accelerated conditions of 40° C, 75 % relative humidity for 1 month.

5 ^bSamples stored at accelerated conditions of 40° C, 75 % relative humidity for 3 months.

It would be evident from the above, that incorporation of a calcium salt such as calcium sulphate as a matrix stabilizing agent advantageously favours maintaining the stability of the composition as a control release formulation, and can maintain its dissolution characteristics after storage at accelerated conditions. Additionally, the use of a hydroxypropyl methylcellulose in addition to a xanthan gum and a sodium alginate, though provides composition, which maintains its physical integrity/shape in the later stages of hydration, it does not provide a composition, which can maintain its dissolution characteristics after 10 storage of samples at accelerated conditions.

15

In accordance the further aspect of the invention the following illustrations demonstrate the selectivity in the use of calcium sulphate within the range of the 8 % -20 % by weight of sodium alginate in the controlled release formulation of the invention.

20

Concentration of calcium sulphate

C) Calcium sulphate at concentration of 5 % by weight of sodium alginate

Ingredients	Weight (mg/tablet)	% w/w
Cephalexin	797.87	73.87
Sodium Alginate	43.20	4.00
Xanthan Gum	54.00	5.00

Hydroxypropyl Methylcellulose (Methocel K15M)	54.00	5.00
Calcium Sulphate	2.16	0.20
Lactose Monohydrate0	112.57	10.42
Magnesium Stearate	16.20	1.50
Weight	1080	100

Time (hour)	% Cephalexin released	
	Initial	1M ^a
1	22.1	24.1
2	34.2	36.3
3	41.3	47.6
4	42.6	47.7
6	46.6	57.4
8	55.0	72.2
10	65.9	86.4
12	72.7	108.9
14	80.1	

^aSamples stored at accelerated conditions of 40° C, 75 % relative humidity for 1 month.

- 5 The above results demonstrate by way of an increase in the dissolution rate of sample stored at accelerated condition, that concentration of calcium salt has not been adequate for maintaining dissolution characteristics after storage at accelerated conditions.

10 **D) Calcium sulphate at concentration of 12 % by weight of sodium alginate**

Ingredients	Weight (mg/unit)	% w/w
Cephalexin	797.87	73.87
Sodium Alginate	43.20	4.00
Xanthan Gum	54.00	5.00
Hydroxypropyl Methylcellulose (Methocel K15M)	54.00	5.00
Calcium Sulphate	5.10	0.47
Lactose Monohydrate	109.63	10.15
Magnesium Stearate	16.20	1.50
Weight	1080	100

Time (hour)	% Cephalexin released	
	Initial	1M ^a
1	22.5	22.6
2	35.7	34.3
3	45.0	42.3
4	44.4	43.7

6	48.5	48.5
8	58.1	58.2
10	69.4	69.9
12	79.1	82.5
14	86.8	91.1

*Samples stored at accelerated conditions of 40° C, 75 % relative humidity for 1 month.

- The dissolution characteristics of sample after storage at accelerated conditions can be
 5 maintained by incorporating appropriate concentration of a calcium salt by weight of sodium alginate.

E) Calcium sulphate at concentration of 25 % by weight of sodium alginate

10

Ingredients	Weight (mg/tablet)	% w/w
Cephalexin	797.87	73.87
Sodium Alginate	43.20	4.00
Xanthan Gum	54.00	5.00
Hydroxypropyl Methylcellulose (Methocel K15M)	54.00	5.00
Calcium Sulphate	10.80	1.00
Lactose Monohydrate	103.93	9.62
Magnesium Stearate	16.20	1.50
Weight	1080	100

Time (hour)	% Cephalexin released
	Initial
1	21.3
2	33.0
3	40.0
4	42.1
6	43.5
8	47.7
10	53.9
12	59.7
14	66.1

The above results reveal that the initial release is retarded when higher concentration of calcium salt is used which is again not acceptable.

15

The above illustrations clearly reveal that only when calcium salt is used in amounts within the range of 8 % - 20 % by weight of sodium alginate, the desired release profile and stability

of the compositions can be maintained which is lost when the amount of calcium salt used is beyond the above selected range.

Tablets without Probenecid -

- 5 Cefaclor or cephalexin, a mixture of uniformly preblended hydrophilic polymers and calcium sulphate, lactose and/or microcrystalline cellulose were mixed uniformly and lubricated with magnesium stearate. The blend was compacted and the slugs obtained were milled to form granules. The sized granules were blended with the fines and the remaining lubricant and further compressed into tablets.

10

- For Example 1 to Example 5, the tablets were tested for cefaclor release in 900 ml of 0.1 N hydrochloric acid for 1 hr, after which the dissolution medium was changed to pH 6.8 phosphate buffer 900 ml. The dissolution medium (pH 6.8 phosphate buffer) was replaced with fresh medium every hour thereafter. The tablets were placed into a 40 mesh basket (USP apparatus type-I) and were rotated at 100 rpm.

- 15 For the examples containing cefaclor the dissolution medium (pH 6.8 phosphate buffer) was replaced with fresh medium every hour thereafter. For the examples containing cephalexin only aliquots and not all of the pH 6.8 phosphate buffer were withdrawn and replaced with
20 fresh medium at each interval.

Example 1

Ingredients	Weight (mg/tablet)	% w/w
Cefaclor	524.10	74.87
Sodium Alginate	24.50	3.50
Xanthan Gum	7.00	1.00
Calcium Sulphate	3.50	0.50
Lactose Monohydrate	126.90	18.12
Magnesium Stearate	14.00	2.00
Total	700	100

Time (hour)	Percent Cefaclor Released (%)
1	30.90
2	47.10
3	68.80
4	83.40

Example 2

Ingredients	Weight (mg/tablet)	% w/w
Cefaclor	524.10	74.87
Sodium Alginate	24.50	3.50
Xanthan Gum	7.00	1.00
Calcium Sulphate	3.50	0.5
Microcrystalline Cellulose	126.90	18.12
Magnesium Stearate	14.00	2.00
Total	700	100

Time (hour)	Percent Cefaclor Released (%)
1	30.30
2	48.80
3	73.10
4	87.90

5

Example 3

Ingredients	Weight (mg/tablet)	% w/w
Cefaclor	526.80	75.25
Sodium Alginate	24.50	3.50
Xanthan Gum	14.00	2.00
Calcium sulphate	3.50	0.50
Lactose monohydrate	117.20	16.74
Magnesium Stearate	14.00	2.00
Total	700	100

Time (hour)	Percent Cefaclor Released (%)
1	24.60
2	35.30
3	46.80
4	66.30
5	83.10
6	94.10

10

15

Example 4

Ingredients	Weight (mg/tablet)	% w/w
Cefaclor	526.80	75.26
Sodium Alginate	24.50	3.50
Xanthan Gum	3.50	0.50
Hydroxypropyl Methylcellulose (Methocel K4M)	10.50	1.50
Calcium Sulphate	4.90	0.70
Lactose monohydrate	115.80	16.54
Magnesium Stearate	14.00	2.00
Total	700	100

5

Time (hour)	Percent Cefaclor Released (%)
1	29.60
2	49.60
3	74.70
4	92.80

Example 5

Ingredients	Weight (mg/tablet)	% w/w
Cefaclor	789.40	75.18
Sodium Alginate	42.00	4.00
Xanthan Gum	15.75	1.50
Hydroxypropyl Methylcellulose (Methocel K4M)	21.00	2.00
Calcium Sulphate	5.88	0.56
Lactose monohydrate	154.97	14.76
Magnesium Stearate	21.00	2.00
Total	1050	100

10

Time (hour)	Percent Cefaclor Released (%)
1	19.10
2	28.70
3	44.40
4	59.80
5	71.40
6	82.00

For Example 6 to Example 11, the tablets were tested for cephalexin release in 900 ml of 0.1 N hydrochloric acid for 2 hr, after which the dissolution media was changed to pH 6.8

phosphate buffer 900 ml. The tablets were placed into a 40 mesh basket (USP apparatus type-I) and were rotated at 100 rpm.

Example 6

Ingredients	Weight (mg/tablet)	% w/w
Cephalexin	536.82	74.55
Sodium Alginate	43.20	6.00
Xanthan Gum	21.60	3.00
Hydroxypropyl Methylcellulose (Methocel K4M)	21.60	3.00
Calcium Sulphate	4.32	0.60
Lactose monohydrate	81.68	11.34
Magnesium Stearate	10.80	1.50
Total	720	100

5

Time (hour)	Percent Cephalexin Released (%)
1	28.60
2	43.90
3	55.80
4	74.10
5	98.20

Example 7

Ingredients	Weight (mg/tablet)	% w/w
Cephalexin	799.95	74.07
Sodium Alginate	64.80	6.00
Xanthan Gum	75.60	7.00
Calcium Sulphate	7.77	0.72
Lactose monohydrate	115.60	10.70
Magnesium Stearate	16.20	1.50
Total	1080	100

Time (hour)	Percent Cephalexin Released (%)
1	22.80
2	35.10
3	42.10
4	42.90
6	47.40
8	57.40
10	73.50
12	86.10
14	98.40

Example 8

Ingredients	Weight (mg/tablet)	% w/w
Cephalexin	800.94	74.16
Sodium Alginate	54.00	5.00
Xanthan Gum	75.60	7.00
Calcium Sulphate	7.56	0.70
Lactose monohydrate	125.70	11.64
Magnesium Stearate	16.20	1.50
Total	1080	100

Time (hour)	Percent Cephalexin Released (%)
1	21.70
2	35.20
3	45.10
4	45.30
6	50.60
8	62.50
10	78.50
12	81.70
14	93.20

5

Example 9

Ingredients	Weight (mg/tablet)	% w/w
Cephalexin	797.87	73.87
Sodium Alginate	64.80	6.00
Xanthan Gum	54.00	5.00
Hydroxypropyl Methylcellulose (Methocel K15M)	54.00	5.00
Calcium Sulphate	7.78	0.72
Lactose monohydrate	79.95	7.40
Magnesium Stearate	21.60	2.00
Total	1080	100

Time (hour)	Percent Cephalexin Released (%)
1	23.20
2	34.90
3	41.40
4	43.30
6	47.10
8	57.10
10	70.10
12	86.90
14	97.00

Example 10

Ingredients	Weight (mg/tablet)	% w/w
Cephalexin	797.87	73.87
Sodium Alginate	64.80	6.00
Xanthan Gum	32.40	3.00
Hydroxypropyl Methylcellulose (Methocel K15M)	32.40	3.00
Calcium Sulphate	7.77	0.72
Lactose monohydrate	128.54	11.90
Magnesium Stearate	16.20	1.50
Total	1080	100

Time (hour)	Percent Cephalexin Released (%)
1	23.90
2	37.10
3	46.30
4	47.20
6	58.70
8	77.60
10	92.10
12	98.20

5 Example 11

Ingredients	Weight (mg/tablet)	% w/w
Cephalexin	797.87	73.87
Sodium Alginate	43.20	4.00
Xanthan Gum	43.20	4.00
Hydroxypropyl Methylcellulose (Methocel K15M)	64.80	6.00
Calcium Sulphate	5.10	0.47
Lactose monohydrate	109.63	10.15
Magnesium Stearate	16.20	1.50
Total	1080	100

Time (hour)	Percent Cephalexin Released (%)
1	22.90
2	35.10
3	42.40
4	43.60
6	47.80
8	57.10
10	66.90
12	76.60
14	86.80

Tablets with Probenecid -**Example 12**

5

Cephalexin, a mixture of uniformly preblended hydrophilic polymers and calcium sulphate, lactose were mixed uniformly and lubricated with magnesium stearate. The blend was compacted and the slugs obtained were milled to form granules. The sized granules were blended with the fines and the remaining lubricant.

10

Probenecid, microcrystalline sodium, sodium starch glycolate, were screened through 30 mesh sieve. The blend was compacted and the slugs obtained were again milled to obtain granules. The sized granules were mixed with remaining sodium starch glycolate and magnesium stearate and fines, followed by compression of cephalexin granules on the pre-compressed probenecid granules.

15

The tablets were tested for cephalexin release in 900 ml of 0.1 N hydrochloric acid for 2 hrs after which the dissolution media was changed to pH 6.8 phosphate buffer 900 ml. The tablets were placed into a 40 mesh basket (USP apparatus type I) and were rotated at 100 rpm. Further, fresh tablets were analysed for Probenecid release using 900 ml of pH 7.5 simulated intestinal fluid without pancreatin, USP apparatus type II at 50 rpm.

20

Ingredients	Weight (mg)	% w/w
Controlled Release Part		
Cephalexin	536.82	74.55
Sodium Alginate	28.80	4.00
Xanthan Gum	21.60	3.00
Hydroxypropyl Methylcellulose (Methocel K4M)	28.80	4.00
Calcium Sulphate	4.03	0.37
Lactose	89.15	12.38
Magnesium Sterate	10.80	1.50
Total	720	100.00
Immediate Release Part		
Probenecid	500.00	79.36
Microcrystalline Cellulose	95.50	15.16
Sodium Starch Glycolate	31.50	5.00
Magnesium Sterate	3.00	0.48
Total	630.00	100.00

Time (hour)	Percent Cephalexin Released (%)
1	25.14
2	37.76
3	44.80
4	47.49
6	63.61
8	78.05
10	96.40

Time (min)	Percent Probenecid Released (%)
10	98.80
20	102.20
30	103.30

Example 13

5

Cephalexin, uniformly preblended hydrophilic polymers and calcium sulphate, microcrystalline cellulose were mixed uniformly and lubricated with magnesium stearate. The blend was compacted and the slugs obtained were milled to form granules. The sized granules were blended with the fines and the remaining lubricant.

10

Probenecid, lactose, sodium starch glycolate were screened through 30 mesh sieve. The blend was compacted and slugs obtained were milled to obtain granules. The sized granules were mixed with remaining sodium starch glycolate, magnesium stearate and fines followed by compression of Cephalexin granules on pre-compressed Probenecid granules.

15

The tablets were tested for dissolution in 900 ml of 0.1 N hydrochloric acid for 2 hrs after which the dissolution media was changed to pH 6.8 phosphate buffer 900 ml, using 40 mesh basket (USP apparatus type I) and were rotated at 100 rpm. Further fresh samples were analysed for Probenecid release using 900 ml of pH 7.5 simulated intestinal fluid without

20 pancreatin, USP apparatus type II at 50 rpm.

Ingredients	Weight (mg/tablet)	% w/w
Controlled Release Part		
Cephalexin	536.82	74.55
Sodium Alginat	43.20	6.00
Xanthan Gum	36.00	5.00
Calcium Sulphate	6.01	0.84

Microcrystalline cellulose	87.13	12.10
Magnesium Sterate	10.80	1.50
Total	720	100
Immediate Release Part		
Probenecid	500.00	79.36
Lactose	102.00	16.19
Sodium Starch Glycolate	25.00	3.97
Magnesium Sterate	3.00	0.48
Total	630.00	100.00

Time (hour)	Percent Cephalexin Released (%)
1	28.10
2	41.80
3	50.30
4	57.30
6	70.10
8	83.30
10	99.70

Time (min)	Percent Probenecid Released (%)
10	80.30
20	95.40
30	99.30

5 Example 14

Cephalexin, probenecid, a mixture of uniformly preblended hydrophilic polymers and calcium sulphate and microcrystalline cellulose were screened through 30 mesh screen and mixed with magnesium stearate. The blend was compacted and the slugs obtained were milled to obtain the granules. The sized granules were blended with fines and the remaining lubricant and further compressed into tablets.

The tablets were tested for cephalexin dissolution in 900 ml of 0.1N hydrochloric acid for 2 hrs after which the dissolution media was changed to pH 6.8 phosphate buffer 900 ml, using 15 40 mesh basket (USP apparatus type I) and were rotated at 100 rpm. Further fresh samples were analysed for probenecid release using 900 ml of pH 7.5 simulated intestinal fluid without pancreatin, USP apparatus type II at 50 rpm.

Ingredients	Weight (mg/tablet)	% w/w
Cephalexin	536.82	38.34

Probenecid	500.00	35.71
Sodium Alginate	70.00	5.00
Xanthan Gum	56.00	4.00
Hydroxypropyl Methylcellulose (Methocel K4M)	70.00	5.00
Calcium Sulphate	7.00	0.50
Microcrystalline cellulose	142.68	10.19
Magnesium Sterate	17.50	1.25
Total	1400	100

Time (hour)	Percent Cephalexin Released (%)	Percent Probenecid Released (%)
1	23.60	42.90
2	42.70	69.70
3	54.60	85.50
4	61.20	100.90
6	70.10	
8	80.40	
10	96.90	

Example 15

- 5 Cefaclor, a mixture of uniformly preblended hydrophilic polymers and calcium sulphate, microcrystalline cellulose were mixed uniformly and lubricated with magnesium stearate. The blend was compacted and the slugs obtained were milled to form granules. The sized granules were blended with the fines and the remaining lubricant.
- 10 Probenecid, starch, sodium starch glycolate, were screened through 30 mesh sieve. The blend was compacted and the slugs obtained were milled to obtain granules. The sized granules were mixed with remaining sodium starch glycolate and magnesium stearate and fines, followed by compression of cefaclor granules on the pre-compressed Probenecid granules.
- 15 The tablets were tested for cefaclor release in 900 ml of 0.1 N hydrochloric acid for 2 hrs after which the dissolution media was changed to pH-6.8 phosphate buffer 900 ml. The tablets were placed into a 40 mesh basket (USP apparatus type-I) and were rotated at 100 rpm. The dissolution medium (pH 6.8 phosphate buffer) was replaced by fresh medium every hour. Further fresh tablet were analysed for Probenecid release using 900 ml of pH 7.5 simulated intestinal fluid without pancreatin, USP apparatus type II at 50 rpm.
- 20

Ingredients	Weight (mg/tablet)	% w/w
Controlled Release Part		
Cefaclor	530.50	75.78
Sodium Alginate	28.00	4.00
Xanthan Gum	7.00	1.00
Hydroxypropyl Methylcellulose (Methocel K4M)	14.00	2.00
Calcium Sulphate	3.92	0.56
Microcrystalline Cellulose	106.08	15.15
Magnesium Sterate	10.50	1.50
Total	700	100
Immediate Release Part		
Probenecid	500.00	79.36
Starch	70.61	11.21
Sodium Starch Glycolate	50.40	8.00
Magnesium Sterate	9.00	1.43
Total	630.00	100.00

Time (hour)	Percent Cefaclor Released (%)
1	24.60
2	45.20
3	50.60
4	61.30
6	75.90
8	89.20

Time (min)	Percent Probenecid Released (%)
10	96.80
20	99.10
30	100.80

5

Further the bioavailability study was conducted for long acting modified release matrix formulation without probenecid, one dose of 2 tablets x (750 mg cephalexin), prepared according to present invention. Eight healthy male volunteers were selected for the study in which each volunteer was administered a dose of the drug with 180 ml of water. The volunteers had a standard breakfast before taking the drug. The desired blood levels up to 18 to 20 hours were achieved with compositions without probenecid prepared according to the invention, indicating that it can be used as once daily composition.

Figure 1 shows a plot of blood level concentrations of modified release composition of the present invention, one dose of 2 tablets of cephalexin 750 mg. The plot clearly reveals the favourable bio-availability of the active achieved using the formulation of the invention.

CLAIMS

- 5 1. A stable improved pharmaceutical composition for controlled release of an active ingredient comprising a controlled release matrix comprising i)a betalactam antibiotic or their pharmaceutically acceptable hydrates, salts or esters as the active ingredient in amounts of 30 % to 90 % by weight, ii)a mix of hydrophilic polymers in amount of 1 % to 25 % selected from the group consisting of at least one sodium alginate in amounts of 0.1 % to 20 %, and at least one xanthan gum in amounts of 0.1 % to 20 % and iii) a calcium salt in an amount of 8 % to 20 % by weight of sodium alginate.
- 10 2. A stable improved pharmaceutical composition as claimed in claim 1 wherein said hydrophilic polymers mix comprise hydroxypropyl methylcellulose in an amount of 0.1 % to 20 % by weight.
- 15 3. A stable improved pharmaceutical composition as claimed in anyone of claims 1 or 2 comprising probenecid.
- 20 4. The composition as claimed in claim 3 wherein the probenecid is present in the controlled release matrix.
- 25 5. The composition as claimed in claim 3 wherein the active is released at a rate suitable for once daily or twice daily administration of the composition.
- 30 6. The composition as claimed in claim 1 in a solid dosage form.
7. The composition as claimed in claim 1 wherein the calcium salt is calcium sulphate.
8. The composition as claimed in claim 2 wherein the controlled release matrix comprises from 30 % to 90 % by weight of a betalactam antibiotic or their pharmaceutically acceptable hydrates, salts or esters and 1 % to 20 % by weight of hydrophilic polymers comprising of a medium or high viscosity grade sodium alginate in an amount from 0.1 % to 15 % by weight, a medium or high viscosity grade xanthan gum in an amount from 0.1 % to 15 % by weight, and a medium or

high viscosity grade hydroxypropyl methylcellulose in an amount from 0.1 % to 15 % by weight of controlled release matrix; and calcium sulphate in an amount from 8 % to 16 % by weight of sodium alginate.


- 5 9. The composition as claimed in claim 2, wherein the controlled release matrix comprises from 30 % to 90 % by weight of a betalactam antibiotic or their pharmaceutically acceptable hydrates, salts or esters and 1 % to 18 % by weight of hydrophilic polymers comprising of a medium or high viscosity grade sodium alginate in an amount from 1 % to 10 % by weight, a medium or high viscosity grade xanthan gum in an amount from 1 % to 10 % by weight, and a medium or high viscosity grade hydroxypropyl methylcellulose in an amount from 1 % to 10 % by weight of controlled release matrix; and calcium sulphate in an amount from 10 % to 14 % by weight of sodium alginate.
- 10 10. The composition as claimed in anyone of claims 1, 8 or 9, wherein the betalactam antibiotic is selected from cephalexin, cefaclor or their pharmaceutically acceptable hydrates, salts or esters.
- 15 11. The composition as claimed in claim 1, wherein the calcium salt is selected from calcium sulphate, calcium citrate, disodium calcium edetate, calcium lactate, calcium ascorbate, calcium gluconate, calcium chloride.
- 20 12. The composition as claimed in claim 1 or 2, which further comprises at least one water soluble or water dispersible diluent.
- 25 13. The composition as claimed in claim 12, wherein the water soluble or water dispersible diluent comprises 1 % to 30 % by weight of the composition.
- 30 14. The composition as claimed in claim 12, wherein the diluent is lactose.
15. The composition as claimed in claim 14, wherein the amount of lactose is from 4 % to 20 % by weight of the composition.

16. The composition as claimed in claim 12, wherein the diluent is microcrystalline cellulose.
- 5 17. The composition as claimed in claim 16, wherein the amount of microcrystalline cellulose is from 4 % to 20 % by weight of the composition.
18. The composition as claimed in claim 1 comprising magnesium stearate, in amount from 0.2 % to 5 % by weight of the composition.
- 10 19. A composition as claimed in any one of the preceding claims wherein a multidose contains 250 mg to 2 g active ingredient.
20. A composition as claimed in anyone of claims 1 to 18 in dosage unit form containing 15 100 to 1 g active ingredient.
21. The composition as claimed in claim 3, wherein probenecid is present in an amount from about 250 mg to about 1000 mg.
- 20 22. The composition as claimed in claim 3, wherein the probenecid is present as a immediate release part.
23. The composition as claimed in claim 22, which further contains a disintegrating agent from 2 % to 9 % by weight of immediate release part.
- 25 24. The composition as claimed in claim 23 wherein disintegrating agent is sodium starch glycolate.
- 30 25. The composition as claimed in claim 22 wherein, the controlled release part in a hydrophilic matrix and immediate release probenecid part are compressed together into a tablet dosage form.

26. The composition as claimed in claim 22 wherein, the controlled release part in a hydrophilic matrix and immediate release probenecid part are compressed separately into tablets and packed in a way to be administered simultaneously.
- 5 27. A process for the preparation of a pharmaceutical composition as claimed in claim 1, comprising mixing together the active ingredient with the pre-blended hydrophilic polymers with or without hydroxypropyl methylcellulose and calcium sulphate, in selective amounts, optionally with one or more of probenecid, diluent and lubricant to form a blend, further compacting, sizing, blending and compressing into tablets.
- 10 28. A process for the preparation of a pharmaceutical composition as claimed in claim 22, comprising mixing together the active ingredient with the pre-blended hydrophilic polymers with or without hydroxypropyl methylcellulose and calcium sulphate together with a diluent and at least one lubricant to form a blend, further compacting, sizing, blending and compressing into tablets along with immediate release probenecid part.
- 15 29. A process for the preparation of pharmaceutical composition as claimed in claim 3, comprising mixing together probenecid, diluent and disintegrating agent together, compacting, sizing and blending with lubricant and compressing the blend into tablets along with controlled release matrix.
- 20

1/1

Figure 1- Linear plot of mean serum concentration v/s time for improved controlled release cephalixin (2×750 mg) dose



INTERNATIONAL SEARCH REPORT

Inte nal Application No
PCT/IN 01/00204

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/22 A61K31/545 A61K31/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, MEDLINE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00 15198 A (STANIFORTH JOHN H ;SEN HIMADRI (IN); TALWAR NARESH (IN); RANBAXY L) 23 March 2000 (2000-03-23) page 14, line 11-14; claim 47; examples ---	1-29
Y	WO 98 22091 A (YISSUM RES DEV CO ;HOFFMAN AMNON (IL); FRIEDMAN MICHAEL (IL); KATZ) 28 May 1998 (1998-05-28) claims 3,10; example 2 ---	1-29
Y	EP 0 234 670 A (BOOTS CO PLC) 2 September 1987 (1987-09-02) page 6, line 13-16 page 7, line 26-31; example 3 ---	1-29 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

T later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed Invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed Invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the International search

5 June 2002

Date of mailing of the international search report

13/06/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Herrera, S

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/IN 01/00204

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DATABASE WPI Section Ch, Week 197741 Derwent Publications Ltd., London, GB; Class B02, AN 1977-73627Y XP002172733 & JP 52 105220 A (TOYAMA CHEM CO LTD), 3 September 1977 (1977-09-03) abstract -----	3-5, 20-26, 28,29

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte	nal Application No
PCT/IN 01/00204	

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 0015198	A 23-03-2000	AU	1779499 A BG 105339 A BR 9913696 A CN 1325299 T CZ 20010901 A3 EP 1107741 A1 HR 20010187 A1 WO 0015198 A1 NO 20011276 A PL 346798 A1 SK 3472001 A3 TR 200100731 T2 ZA 9905839 A	03-04-2000 30-11-2001 09-10-2001 05-12-2001 15-08-2001 20-06-2001 30-04-2002 23-03-2000 10-05-2001 25-02-2002 08-10-2001 21-06-2001 28-03-2000
WO 9822091	A 28-05-1998	AU EP WO	4882597 A 0941064 A1 9822091 A1	10-06-1998 15-09-1999 28-05-1998
EP 0234670	A 02-09-1987	AT AU AU AU AU CA DE DE DK EP ES FI GR IE IL IN JP JP JP KR MX NO NZ PH PT US ZA	77548 T 608208 B2 6762587 A 628754 B2 7946291 A 1313133 A1 3779933 D1 3779933 T2 14887 A 0234670 A2 2042541 T3 870155 A ,B, 3005796 T3 59333 B 81281 A 164250 A1 1940551 C 6069965 B 62181227 A 9411242 B1 4949 A 173317 C 218907 A 26408 A 84133 A ,B 5415871 A 8700173 A	15-07-1992 28-03-1991 23-07-1987 17-09-1992 12-09-1991 26-01-1993 30-07-1992 10-12-1992 19-07-1987 02-09-1987 16-12-1993 19-07-1987 07-06-1993 09-02-1994 29-11-1990 04-02-1989 09-06-1995 07-09-1994 08-08-1987 03-12-1994 01-12-1993 01-12-1993 29-05-1989 02-07-1992 01-02-1987 16-05-1995 26-08-1987
JP 52105220	A 03-09-1977	JP JP	1330787 C 60055486 B	14-08-1986 05-12-1985